A trial fibrillation (AF) is common, and the prevalence will increase as the population ages. 1 Patients with AF often have other comorbidities and undergo invasive cardiac and noncardiac procedures that require interruption of anticoagulant therapy. Routine clinical care procedures can be either elective or urgent, requiring different approaches to management of anticoagulant therapy with rapid reversal or careful planning with potential bridging therapy. In clinical trials, interruption of study drug therapy for similar procedures is anticipated, and guidelines or recommendations are provided for site investigators. In contrast to clinically mandated interruptions during the trial, at the end of the blinded Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial In Atrial Fibrillation (ROCKET AF) study, there was a necessary but artificial discontinuation of study therapy and a necessary transition to open-label vitamin K antagonist (VKA) therapy.
on their assigned therapy at the EOS. 3 The US Food and Drug Administration issued a black box warning in the prescribing information for rivaroxaban, cautioning providers that discontinuing rivaroxaban could increase the risk of thrombotic events. 4 The analyses presented here further evaluate the ROCKET AF findings and provide potential explanations.
Methods
The ROCKET AF study has been described previously. 2, 3 Briefly, the study was a multicenter, randomized, double-blind, double-dummy, event-driven trial comparing rivaroxaban (20 mg daily; 15 mg daily in participants with creatinine clearance 30-49 mL/min) with adjusted-dose warfarin (target international normalized ratio [INR], 2.0-3.0) for prevention of stroke or systemic embolism. 2, 3 The study was supported by Johnson & Johnson Pharmaceutical Research & Development (Raritan, NJ) and Bayer HealthCare AG (Leverkusen, Germany), and an international executive committee designed the study and oversaw the trial conduct. The protocol was approved by national regulatory authorities and ethics committees at participating centers. All participants provided written consent.
Study Participants and Follow-up
Participants with nonvalvular AF at moderate to high risk of stroke were recruited at 1178 participating sites in 45 countries. Participants who were included had a history of stroke, transient ischemic attack, or systemic embolism or ≥2 (capped at 10%) or 3 of the following: heart failure or left ventricular ejection fraction ≤35%, hypertension, ≥75 years of age, or diabetes mellitus (CHADS 2 score ≥2). Participants were followed up monthly for assessment of clinical outcomes and adverse events and monitoring of INR values while on therapy. If study drug was discontinued before the EOS, participants were to be contacted by telephone every 3 months for ascertainment of events.
An independent clinical end point committee applied protocol definitions to adjudicate all suspected stroke, systemic embolism, myocardial infarction, death, and bleeding events, including those after the EOS visit, although blinded to treatment assignment.
EOS Recommendations
Recommendations for EOS transition to open-label anticoagulation were provided to site investigators and coordinators through Webinars, frequently asked question documents, and a clinical helpline. If openlabel VKA was indicated, investigators were instructed to start that therapy on the day of the EOS visit and to simultaneously discontinue study medication. To maintain the study blind, an unblinded INR was to be collected on the third day after the EOS visit. If the INR was subtherapeutic, investigators were encouraged to consider bridging therapy with enoxaparin or unfractionated heparin, if the participant was considered high risk for thromboembolism according to local standards and practices based on the unblinded INR. Investigators were advised to carefully select the appropriate dose of VKA that would obtain an INR of 2.0 to 3.0 or to consider using a dose similar to that used before entry in the trial. Investigators could also call a clinical helpline for assistance if a nonwarfarin VKA was going to be used.
Investigators were instructed to submit all INR values gathered during the transition phase and report all adverse events and safety and efficacy events for adjudication. All participants still on study drug at the end of the trial were to be seen 30 days after the EOS visit for a final study visit.
Statistical Analysis
By design, ROCKET AF was a noninferiority trial, and the primary analysis was performed in the per-protocol, on-treatment population. 2, 3 These analyses were also performed on this population to explore the consequences of transition from study drug to standard clinical care at the end of the trial in participants still on study drug. The end of the on-treatment period was defined as the last study drug administration plus 2 days to account for continued drug effect. Therefore, the focus of these analyses is on days 3 to 30 after study drug discontinuation.
Descriptive statistics of baseline characteristics are given as numbers and percentages or medians with 25th and 75th percentiles, as appropriate. Event rates are presented as per 100 patient-years. The primary end point for this analysis was the primary efficacy end point in the trial, the composite of any stroke or noncentral nervous system systemic embolism. Secondary end points included both efficacy and safety end points from the trial. With respect to the time to each end point, an unadjusted Cox proportional hazards model was used to evaluate the association between rivaroxaban versus warfarin and risk of event. Risk relationships are expressed as hazard ratios with 95% confidence intervals derived from the Cox models. The time to attainment of therapeutic INR (≥2) within 30 days after study drug discontinuation was compared between treatment arms with a logrank test. Analyses of INR values and comparison of event rates during the trial and after the EOS visit are considered exploratory. All statistical analyses were performed with SAS software (version 9.2, SAS Institute, Inc, Cary, NC).
All subjects enrolled in the study gave informed consent. All appropriate national regulatory authorities and ethics committees at participating centers approved the study.
Results
Overall, 9248 (65%) of the 14 143 per-protocol, on-treatment participants in ROCKET AF were still taking study drug at the EOS visit. Baseline characteristics in participants on study drug at the EOS visit are shown in Table 1 . Participants completing the study still on study drug tended to be younger, had better renal function, and had generally less comorbidity but had more previous stroke or transient ischemic attack, although the differences are minor. These characteristics were balanced between the treatment groups in participants on study drug at the EOS.
At 
WHAT IS KNOWN
• An excess of thromboembolic events occurred in the ROCKET AF trial during the 30 days after the end of study visit when participants transitioned from blinded therapy to open-label vitamin K antagonist. • The excess in events during the transition phase resulted in a US Food and Drug Administration black box warning in the prescribing information for rivaroxaban cautioning providers that discontinuation could increase the risk of thrombotic events.
WHAT THE STUDY ADDS
• These analyses provide clinicians with a possible explanation for the excess in events at the end of the study. • Based on these data, clinicians transitioning a patient with atrial fibrillation from rivaroxaban to a vitamin K antagonist should do so with careful dosing and monitoring to ensure consistent and adequate anticoagulation. Figure 1 shows the stroke and systemic embolic events that occurred in participants still on study drug at the EOS visit. For days 3 to 30, which were defined as off treatment, there was an excess of events in the participants assigned to rivaroxaban compared with those assigned to warfarin (rivaroxaban 22 events, event rate 6.42; warfarin 6 events, event rate 1.73; hazard ratio, 3.72; 95% confidence interval [1.51-9.16];
P=0.0044). Three events occurred during the first 2 days after EOS and were not included in the analyses for 3 to 30 days (rivaroxaban 0 events; warfarin 3 events). The rates of stroke and systemic embolism within 30 days after the EOS visit were similar in participants who completed the study and did not transition to open-label VKA (n=724; 0.31%) compared with participants who did transition to open-label VKA (n=8524; 0.28%), although the number of participants and events is small.
Detailed information for each of the 28 participants with stroke or systemic embolic events that occurred between 3 and 30 days after the EOS visit is shown in Table 2 . The mean CHADS 2 score in these participants was higher than the overall trial (4.12 versus 3.48), and a higher proportion of participants had previous stroke, transient ischemic attack, or systemic embolism compared with the overall trial (86% versus 55%). Table 3 shows all efficacy and cardiovascular outcomes occurring between 3 and 30 days after the EOS visit in participants still on study drug at the EOS. Few myocardial infarctions occurred (rivaroxaban 1; warfarin 2). A total of 22 deaths were reported (rivaroxaban 14; warfarin 8), but the rates per 100 patient-years were low. None of the 4 hemorrhagic strokes in the rivaroxaban group occurred in participants treated with bridging therapy. Figure 2A ). Of the 5589 participants who transitioned to open-label VKA at the EOS visit having ≥2 INR measurements within 30 days of study drug discontinuation, 63.0% (1748/2775) of warfarin participants and 33.0% (928/2814) of rivaroxaban participants had ≥2 INRs ≥2 (P<0.0001; Figure 2B ). Table 5 shows the distribution of the 28 stroke and systemic embolic events and event rates between 3 and 30 days after the EOS visit and the number of INR measurements available by geographic region. Regions with more INR assessments had numerically fewer stroke or systemic embolic events.
In participants on study drug at the EOS, the median (25th-75th) time from last dose of study drug and start of open-label VKA therapy was 1 (1-2). A total of 92% of participants who were transitioned did so on the same day as the EOS visit or the day after. The transition time and proportions were balanced between the assigned study drug groups.
Another period of transition of anticoagulation therapy was at the beginning of the trial. Of the 8834 (62%) participants on VKA therapy at the time of randomization, there were 20 strokes or systemic emboli during the first 30 days of the study after the transition from VKA therapy to blinded study drug (8 rivaroxaban, 12 warfarin). In the same population, major bleeding within 30 days was uncommon, and the rates were similar (19 rivaroxaban, 17 warfarin). The median screening INR in participants with major bleeding was 2.4 (1.7-2.7) compared with 1.9 (1.5-2.3) for participants with no bleeding. Figure 3 shows stroke and systemic embolic events in participants assigned to receive warfarin and not on VKA therapy at the screening visit. A total of 8 events occurred during the initiation of warfarin in this participant subgroup without a clustering of early events, suggesting EOS was a unique and artificial period of transition.
Table 3. HR and 95% CIs for Time to First Occurrence of All Efficacy End Points, and Safety End Points of Major and Minor Bleeding (All Adjudicated by CEC) From Day 3 to Day 30 After Last Dose for Participants Who Completed Study Medication

Discussion
In the ROCKET AF trial, 9248 (65%) participants remained on study drug until the end of the trial. After participants were seen at the EOS visit and transitioned to open-label VKA therapy at the discretion of their physician, an excess of stroke and systemic embolic events were observed in the subsequent 28 days in participants who had been assigned to receive rivaroxaban compared with those who had been assigned to receive warfarin. These analyses support the hypothesis that the excess of events (rivaroxaban, 22 versus warfarin, 6) was likely because of a period of inadequate anticoagulation in rivaroxaban participants transitioned to VKA therapy.
The reason for the period of inadequate anticoagulation is not clear. The protocol intentionally did not stipulate a prescribed algorithm for transition; therefore, physicians could manage participants using local standards, including anticoagulation clinics or clinical practice algorithms for management of VKA therapy. However, site investigators were advised through the use of study memos, flyers, and live Webcasts about the appropriate transition to open-label VKA therapy. Lack of reporting of INR values rather than lack of measuring the values may have contributed because ≈5% of participants did not have an INR checked between 3 and 30 days after rivaroxaban was stopped at EOS. The regions with more frequent INR monitoring reported the fewest events, and, overall, there was no apparent relationship between number of INR values reported and event rates after the EOS visit. However, appropriate adjustment of therapy is a factor as well, and we were unable to explore this with the data collected. Importantly, although no evidence of a rebound phenomenon was observed, it is not entirely excluded. However, these data from ROCKET AF and related clinical trial experiences with rivaroxaban make rebound unlikely, although the populations and stroke risk are different in these other cohorts. Key observations, including the pattern of events with a lack of clustering in the days shortly after rivaroxaban cessation, the absence of excess events during other periods of the trial when participants either temporarily or permanently stopped rivaroxaban, 5 and the lack of a similar pattern of events in trials of rivaroxaban in deep vein thrombosis, pulmonary embolism, and after orthopedic surgery provide clinical evidence to support a lack of a rebound phenomenon. 6 Several trial methodologies have been used to censor events during long-term, event-driven trials, and no consensus exists on the best approach. Some clinical trialists have censored on the date the sites were notified (site notification) that the requisite number of events had occurred. Others have censored on the date the participant was seen after site notification and study therapy was discontinued (EOS visit), and others have censored at various intervals after the EOS visit, including 30 days, when the participant may be contacted a final time for ascertainment of safety or efficacy events poststudy drug cessation. For ROCKET AF, it was prespecified that primary analyses include events that occurred up to site notification, but we reported the events after site notification for full transparency in the primary publication. Investigators from 2 other large trials of AF have not reported information about events after EOS in publications to date. 7, 8 Consistent approaches should be considered so that trial data are comparable and transparency is achieved.
During ROCKET AF and before unblinding of the data, the trial leadership was informed about the preliminary results of the Japanese ROCKET trial and a modest excess in events after discontinuation of rivaroxaban compared with warfarin. 9 The trial leadership notified the ROCKET AF data safety monitoring board (DSMB) about these data from the Japanese-ROCKET trial to seek any recommendation about EOS transition. The DSMB informed the trial leadership that participants should have an unblinded INR within a very short time period after discontinuation of study medication, for example, 3 to 5 days (mean 4 days), to determine the adequacy of anticoagulation. The ROCKET AF executive committee considered several options for transition from rivaroxaban to open-label VKA therapy at the EOS visit. The approach implemented represented an attempt to maintain participant safety, provide continued effective anticoagulation, protect the study blind, and limit bias in reporting of events at the end of the trial.
Discontinuation of anticoagulant therapy in patients with AF would be expected to result in an increase in the rate of thromboembolic events attributable to removal of effective therapy. The observed stroke and systemic embolic event rate after EOS in ROCKET AF was 6.42 and consistent with rates (5.4-7.5) reported in similar AF populations. 10, 11 No clinical trial data are available to guide physicians when converting patients from rivaroxaban to warfarin. Rivaroxaban affects the INR, and, therefore, INR measurements may not accurately reflect the VKA effect when both VKA and rivaroxaban are present. The rivaroxaban package insert suggests that when a clinical situation requires discontinuation of rivaroxaban, the physician could "discontinue XARELTO and begin both a parenteral anticoagulant and warfarin at the same time the next dose of XARELTO would have been taken." Alternatively, we suggest that rivaroxaban could be continued while warfarin is started, and rivaroxaban could be stopped when the INR measured at rivaroxaban trough is ≥2.0. The experience of overlap of rivaroxaban with warfarin at the beginning of the trial when VKA-experienced participants were randomly assigned to rivaroxaban with no excess of stroke, systemic embolic, or major bleeding events in the first 30 days of the trial provides circumstantial evidence of the safety of overlapping rivaroxaban and warfarin. However, in this setting, participants had rivaroxaban added to warfarin temporarily rather than warfarin added to rivaroxaban as occurred at the EOS visit.
Several limitations should be acknowledged. Site investigators were instructed to report INR values after the EOS visit on the electronic case report form; however, we suspect but cannot confirm that some values may not have been reported. Not all participants were transitioned to open-label VKA therapy, and the decision to do so was made by the local physician; hence, it was not random. Therefore, potential biases may have been introduced that could neither be identified nor evaluated. No prospective clinical outcome trials have evaluated either the use of bridging therapy 12 or the strategy of overlapping of rivaroxaban and warfarin; therefore, the risks and benefits of these approaches are not known.
Conclusions
An excess in stroke and systemic embolic events during the EOS transition from rivaroxaban to open-label VKA occurred in participants assigned to receive rivaroxaban compared with warfarin in ROCKET AF. The pattern of events was not consistent with a rebound phenomenon. The excess events were likely associated with a period of inadequate therapeutic levels of anticoagulation during transition to VKA therapy, which was attributable to study-specific procedures implemented in part to protect the study blind. If a clinical situation requires rivaroxaban therapy to be stopped and a participant transitioned to VKA therapy, then suggested transition strategies include overlapping rivaroxaban and warfarin until the INR is ≥2.0 taken at the rivaroxaban trough. An alternative strategy is to stop rivaroxaban and simultaneously start parenteral anticoagulation and VKA therapy.
